Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Belimumab by GSK for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Belimumab is under clinical development by GSK and currently in Phase III for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase...
Belimumab by GSK for Cryoglobulinemia: Likelihood of Approval
Belimumab is under clinical development by GSK and currently in Phase II for Cryoglobulinemia. According to GlobalData, Phase II drugs...
Belimumab by GSK for Graves' Ophthalmopathy: Likelihood of Approval
Belimumab is under clinical development by GSK and currently in Phase II for Graves' Ophthalmopathy. According to GlobalData, Phase II...
Belimumab by GSK for Graves Diseases: Likelihood of Approval
Belimumab is under clinical development by GSK and currently in Phase II for Graves Diseases. According to GlobalData, Phase II...
Belimumab by GSK for Graft Versus Host Disease (GVHD): Likelihood of Approval
Belimumab is under clinical development by GSK and currently in Phase I for Graft Versus Host Disease (GVHD). According to...